Open AccessCorrection: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Author(s) -
Manish A. Shah,
Zev A. Wainberg,
Daniel V.T. Catenacci,
Howard S. Höchster,
James M. Ford,
Pamela L. Kunz,
Fa-Chyi Lee,
Howard Kallender,
Franco Cecchi,
Daniel C. Rabe,
Harold Keer,
AnneMarie Martin,
Yuan Liu,
Robert Gag,
Peter L. Bonate,
Li Liu,
Tona M. Gilmer,
Donald P. Bottaro
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0261994
Subject(s) - dosing , cancer , medicine , vegf receptors , oncology , pharmacology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom